Virax Biolabs Group Ltd VRAX

Healthcare SIC 2835 - In Vitro & In Vivo Diagnostic Substances NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —

Market cap —

52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—

P/E—

P/FCF—

EV/EBITDA—

Dividend yield—

Diluted EPS—

Annual financial statements

Income statement

Fiscal year	FY2026	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Operating income	—	-$6.2M	-$6.5M	-$5.7M	-$1.7M	-$644.5K	—
Net income	—	-$6.1M	-$6.7M	-$5.5M	-$1.7M	-$672.9K	—

Balance sheet

Fiscal year	FY2026	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Total assets	—	$6.4M	$5.5M	$9.8M	$48.7K	$39.6K	—
Total equity	—	$5.5M	$5.1M	$8.9M	-$1.2M	-$831.8K	-$1.2M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-295158.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)

Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity

Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks

No annual figures to plot for this company yet.

Others in SIC 2835

Ticker	Company	Market cap	P/E	Revenue growth
IDXX	IDEXX LABORATORIES INC /DE	$42.18B	40.9x	10.4%
LNTH	Lantheus Holdings, Inc.	$6.59B	29.6x	0.5%
CLDX	Celldex Therapeutics, Inc.	$3.12B	—	-78.0%
NEOG	NEOGEN CORP	$2.58B	—	-2.7%
NTLA	Intellia Therapeutics, Inc.	$1.79B	—	16.9%
QDEL	QuidelOrtho Corp	$958.0M	—	-1.9%
ACHV	ACHIEVE LIFE SCIENCES, INC.	$873.6M	—	—
TKNO	Alpha Teknova, Inc.	$371.5M	—	7.4%